Incidence of pseudotumor cerebri before and after December 1996
| . | No. of patients evaluable for pseudotumor cerebri . | Yes,* no. (%) . | No, no. (%) . | P . |
|---|---|---|---|---|
| Before | 263 | 5 (1.9) | 258 (98.1) | |
| After | 536 | 11 (2.0) | 525 (98.0) | |
| .8861 |
| . | No. of patients evaluable for pseudotumor cerebri . | Yes,* no. (%) . | No, no. (%) . | P . |
|---|---|---|---|---|
| Before | 263 | 5 (1.9) | 258 (98.1) | |
| After | 536 | 11 (2.0) | 525 (98.0) | |
| .8861 |
In December 1996, the protocol was amended and methylprednisolone was introduced as prophylaxis for RAS.
Among the 16 patients who experienced pseudotumor cerebri, 10 (62.5%) had less than 18 years.